Clinical operations

What oncology trial drug costs mean for site readiness

Review the zola-cel patient death disclosure, preliminary Breakfree-2 multiple sclerosis data, and implications for CAR-T trial safety and monitoring.

By Lampgen Clinical Research

1 min read · estimated

Sources
$7.58M$58.92M
Estimated median drug acquisition cost overall and for Phase 3 trials

What the source reported

A JAMA Network Open review of 1,378 federally sponsored cancer trials estimated median trial-level drug acquisition costs of $7.58 million overall and $58.92 million for Phase 3. These figures model direct purchase of the study drugs. Actual trial expenditures depend in part on supply arrangements.

What this means for trial teams

When investigational products are expensive or scarce, pharmacy readiness and inventory controls affect both enrollment and continuity of treatment. Before activation, teams can verify storage capacity, agree on temperature-excursion escalation, and connect site enrollment forecasts to resupply plans.

Sources

  1. JAMA Network Open systematic review
  2. Original Lampgen LinkedIn post

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?